Bipolar Disorder, Major Depressive Disorder
Conditions
Brief summary
Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.
Interventions
None listed
Sponsors
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
University Hospitals Cleveland Medical Center
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24 * Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study * Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder * Patient must be at least 18 years old * Patient must be willing to give a blood sample
Exclusion criteria
* Patient lacks the capacity to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genetic markers associated with treatment response | Up to 1.5 years | Genetic markers in PPARG, 5-HT2A, CYP3A4 and CYP2C8 genes known to be related in the pharmacodynamics and pharmacokinetics of pioglitazone or quetiapine XR will be associated with treatment response. |
Countries
United States
Outcome results
None listed